Inmune Bio Files 8-K: Material Agreement and Other Events

TL;DR

INMB filed an 8-K for a material definitive agreement & other events. Details TBD.

AI Summary

On April 19, 2024, Inmune Bio, Inc. entered into a material definitive agreement. The company also reported other events and filed financial statements and exhibits as part of this 8-K filing. The specific details of the agreement and financial information are not fully disclosed in the provided text.

Why It Matters

This filing indicates a significant development for Inmune Bio, Inc. with the entry into a material definitive agreement, which could impact its business operations and future prospects.

Risk Assessment

Risk Level: medium — The filing indicates a material definitive agreement, which could represent significant opportunities or risks depending on the nature of the agreement, but specific details are not provided.

Key Players & Entities

• Inmune Bio, Inc. (company) — Registrant
• April 19, 2024 (date) — Date of earliest event reported
• Nevada (jurisdiction) — State of incorporation
• 001-38793 (identifier) — Commission File Number
• 47-5205835 (identifier) — IRS Employer Identification No.
• Boca Raton, FL (location) — Principal Executive Offices

FAQ

Key Financial Figures

• $0.001 — ch registered Common Stock, par value $0.001 per shares INMB The NASDAQ Stock Ma
• $8.32 — Shares were sold at a purchase price of $8.32 per Share and Warrant, for aggregate gr
• $4,771,289, b — roceeds to the Company of approximately $4,771,289, before deducting placement agent fees and
• $8.445 — ing price for the Shares and Warrant of $8.445 per Share and Warrant. The exercise pr
• $9 — The exercise price of the Warrants is $9.152, which is 10% above the offering pe

Filing Documents

• ea0204329-8k_inmune.htm (8-K) — 35KB
• ea020432901ex5-1_inmune.htm (EX-5.1) — 14KB
• ea020432901ex10-1_inmune.htm (EX-10.1) — 215KB
• ea020432901ex10-2_inmune.htm (EX-10.2) — 67KB
• ea020432901ex10-3_inmune.htm (EX-10.3) — 93KB
• ea020432901ex99-1_inmune.htm (EX-99.1) — 11KB
• ex5-1_001.jpg (GRAPHIC) — 5KB
• 0001213900-24-034982.txt ( ) — 718KB
• inmb-20240419.xsd (EX-101.SCH) — 3KB
• inmb-20240419_lab.xml (EX-101.LAB) — 33KB
• inmb-20240419_pre.xml (EX-101.PRE) — 22KB
• ea0204329-8k_inmune_htm.xml (XML) — 4KB

01 Entry into a Material Definitive Agreement

Item 1.01 Entry into a Material Definitive Agreement. On April 19, 2024, INmune Bio, Inc. (the "Company"), entered into a securities purchase agreement (the "Purchase Agreement") with the purchasers set forth on the signature page thereto (the "Purchasers") for the purchase and sale of an aggregate of 571,592 shares of the Company's common stock (the "Shares") and common stock warrants to purchase 571,592 shares of its common stock ("Warrants") in a registered direct offering. The Shares were sold at a purchase price of $8.32 per Share and Warrant, for aggregate gross proceeds to the Company of approximately $4,771,289, before deducting placement agent fees and expenses. Directors and officers participating in the offering will pay a combined offering price for the Shares and Warrant of $8.445 per Share and Warrant. The exercise price of the Warrants is $9.152, which is 10% above the offering per share price. The Warrants terminate on the earlier of (1) the two (2) year anniversary of the initial exercise date of the Warrant or (2) thirty (30) trading days following the reporting of top line data (EMACC) in the Phase 2 Alzheimer's program of XPro1595 (the "Termination Date") but not thereafter, provided however, in the event that the Warrant is held by directors, officers or other affiliates of the Company and the Termination Date is during a period that such officers, directors or affiliates are subject to a blackout with respect to trading in the Company's common stock, such officers, directors or affiliates will have an additional 60 days from the termination of the blackout date to exercise the Warrant.. Pursuant to a placement agency agreement (the "Placement Agency Agreement") dated as of April 19, 2024, between the Company and LifeSci Capital LLC (the "Placement Agent Agreement," the Company engaged the Placement Agent to act as the Company's sole placement agent in connection with the registered direct offering. Pursuant to the Placement Agency Agreement

01 Other Events

Item 8.01 Other Events. On April 22, 2024 the Company issued a press release regarding the registered direct offering. A copy of the press release is attached as Exhibit 99.1 hereto.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. Exhibit No Exhibit 5.1 Opinion of Sichenzia Ross Ference Carmel LLP 10.1 Form of Securities Purchase Agreement 10.2 Form of Placement Agency Agreement 10.3 Form of Warrant 99.1 Press release 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 1

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. INMUNE BIO INC. Date: April 22, 2024 By: /s/ David Moss David Moss Chief Financial Officer 2

View Full Filing

View this 8-K filing on SEC EDGAR